522 related articles for article (PubMed ID: 17323595)
21. Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatment-resistant hypertension.
Oliver JJ; Hughes VE; Dear JW; Webb DJ
Hypertension; 2010 Jul; 56(1):62-7. PubMed ID: 20479335
[TBL] [Abstract][Full Text] [Related]
22. Summaries for patients. Sildenafil increases exercise capacity in low-oxygen settings.
Ann Intern Med; 2004 Aug; 141(3):I12. PubMed ID: 15289233
[No Abstract] [Full Text] [Related]
23. Acute haemodynamic responses to inhaled nitric oxide and intravenous sildenafil in distal chronic thromboembolic pulmonary hypertension (CTEPH).
Suntharalingam J; Hughes RJ; Goldsmith K; Doughty N; George P; Toshner M; Sheares KK; Pepke-Zaba J
Vascul Pharmacol; 2007 Jun; 46(6):449-55. PubMed ID: 17368113
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy with oral sildenafil and beraprost for pulmonary arterial hypertension associated with CREST syndrome.
Miwa K; Matsubara T; Uno Y; Yasuda T; Sakata K; Tsuda T; Kanaya H
Int Heart J; 2007 May; 48(3):417-22. PubMed ID: 17592207
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic approaches to pulmonary hypertension in hemoglobinopathies: Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathy.
Derchi G; Forni GL
Ann N Y Acad Sci; 2005; 1054():471-5. PubMed ID: 16339700
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
[TBL] [Abstract][Full Text] [Related]
27. Perioperative sildenafil therapy for pulmonary hypertension in infants undergoing congenital cardiac defect closure.
El Midany AA; Mostafa EA; Azab S; Hassan GA
Interact Cardiovasc Thorac Surg; 2013 Dec; 17(6):963-8. PubMed ID: 23985411
[TBL] [Abstract][Full Text] [Related]
28. Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension.
Baliga RS; Zhao L; Madhani M; Lopez-Torondel B; Visintin C; Selwood D; Wilkins MR; MacAllister RJ; Hobbs AJ
Am J Respir Crit Care Med; 2008 Oct; 178(8):861-9. PubMed ID: 18689467
[TBL] [Abstract][Full Text] [Related]
29. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition.
Botha P; Parry G; Dark JH; Macgowan GA
J Heart Lung Transplant; 2009 Jul; 28(7):676-82. PubMed ID: 19560695
[TBL] [Abstract][Full Text] [Related]
30. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension.
Blanco I; Gimeno E; Munoz PA; Pizarro S; Gistau C; Rodriguez-Roisin R; Roca J; Barberà JA
Am J Respir Crit Care Med; 2010 Feb; 181(3):270-8. PubMed ID: 19875684
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic applications of sildenafil citrate in the management of paediatric pulmonary hypertension.
Leibovitch L; Matok I; Paret G
Drugs; 2007; 67(1):57-73. PubMed ID: 17209664
[TBL] [Abstract][Full Text] [Related]
32. Therapy with sildenafil or bosentan decreases pulmonary vascular resistance in patients ineligible for heart transplantation because of severe pulmonary hypertension.
Perez-Villa F; Farrero M; Sionis A; Castel A; Roig E
J Heart Lung Transplant; 2010 Jul; 29(7):817-8. PubMed ID: 20363156
[No Abstract] [Full Text] [Related]
33. Sildenafil improves walk distance in idiopathic pulmonary fibrosis.
Collard HR; Anstrom KJ; Schwarz MI; Zisman DA
Chest; 2007 Mar; 131(3):897-899. PubMed ID: 17356110
[TBL] [Abstract][Full Text] [Related]
34. Sildenafil for the treatment of pulmonary hypertension in pediatric patients.
Huddleston AJ; Knoderer CA; Morris JL; Ebenroth ES
Pediatr Cardiol; 2009 Oct; 30(7):871-82. PubMed ID: 19705181
[TBL] [Abstract][Full Text] [Related]
35. Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension.
Hemnes AR; Champion HC
Expert Rev Cardiovasc Ther; 2006 May; 4(3):293-300. PubMed ID: 16716091
[TBL] [Abstract][Full Text] [Related]
36. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension.
Ghofrani HA; Rose F; Schermuly RT; Olschewski H; Wiedemann R; Kreckel A; Weissmann N; Ghofrani S; Enke B; Seeger W; Grimminger F
J Am Coll Cardiol; 2003 Jul; 42(1):158-64. PubMed ID: 12849677
[TBL] [Abstract][Full Text] [Related]
37. Sildenafil in neonatal pulmonary hypertension due to impaired alveolarisation and plexiform pulmonary arteriopathy.
Chaudhari M; Vogel M; Wright C; Smith J; Haworth SG
Arch Dis Child Fetal Neonatal Ed; 2005 Nov; 90(6):F527-8. PubMed ID: 16244212
[TBL] [Abstract][Full Text] [Related]
38. [Phosphodiesterase inhibitors in clinical practice. The present and the future. Part II].
Baksheev BI; Kolomiets NM
Klin Med (Mosk); 2007; 85(4):4-11. PubMed ID: 17564028
[TBL] [Abstract][Full Text] [Related]
39. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide.
Lepore JJ; Maroo A; Bigatello LM; Dec GW; Zapol WM; Bloch KD; Semigran MJ
Chest; 2005 May; 127(5):1647-53. PubMed ID: 15888841
[TBL] [Abstract][Full Text] [Related]
40. [Drug combination treatment for pulmonary arterial hypertension].
Ghofrani HA; Hoeper MM
Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S330-3. PubMed ID: 17139600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
